Stockholders Approve Reverse Stock Split Proposal for Onconetix, Inc.
Summary
Onconetix, Inc. stockholders approved a reverse stock split proposal, allowing the Board to implement a split ratio between 1-for-2 and 1-for-50 to address the company's low share price.
Key Events
-
Reverse Stock Split Approved
Stockholders approved an amendment to the company's certificate of incorporation to effect a reverse stock split of common stock.
-
Board Discretion on Ratio and Timing
The Board of Directors has the authority to determine the exact split ratio, ranging from 1-for-2 to 1-for-50, at any time prior to the one-year anniversary of the special meeting.
-
Follows Prior Disclosure
This approval finalizes the proposal initiated with the DEF 14A filing on January 2, 2026, which sought stockholder authorization for the reverse split.
Analysis
Onconetix, Inc. stockholders have approved a reverse stock split, granting the Board of Directors discretion to implement a ratio between 1-for-2 and 1-for-50 within the next year. This follows the company's DEF 14A filing on January 2, 2026, which sought this approval. Given the company's micro-cap status and its stock trading near 52-week lows, this action is likely a critical step to maintain listing compliance on Nasdaq, which typically has minimum bid price requirements. While it provides a mechanism to increase the per-share price, reverse stock splits are often viewed negatively by the market as they can signal underlying financial distress or an attempt to avoid delisting, and do not fundamentally change the company's valuation.
At the time of this filing, ONCO was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $1.15 to $56.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.